(VIANEWS) – The NASDAQ ended the session with Novavax rising 5.91% to $19.99 on Tuesday, after five sequential sessions in a row of losses. NASDAQ rose 0.25% to $10,829.50, after five consecutive sessions in a row of losses, on what was a somewhat up trend exchanging session today.
Novavax, Inc. is a biotechnology firm that focuses on vaccine development and commercialization. This company serves as a catalyst for the prevention of serious infections and addresses health care needs. Among the vaccine candidates are NVX–CoV2373, a candidate coronavirus vaccine, which is currently in 2 Phase III trials and 1 Phase IIb trial. NanoFlu is a candidate nanoparticle seasonal quadrivalent flu vaccine that is currently in Phase 3. ResVax is a candidate respiratory syncytialvirus (RSV), fusion (F) nanoparticle vaccine. The company is currently developing RSV F vaccine, which is being tested in Phase II clinical trials for adults aged 60 years or older. It also has a Phase I clinical trial in pediatrics. Takeda Pharmaceutical Company Limited has signed a cooperation agreement for the production, commercialization, and development of NVXCoV2373 (a COVID-19 candidate vaccine). Novavax, Inc., was founded in 1987. It is located in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-7.27.
Return on Equity (TTM)
Novavax’s ROE is -238.6%.
Today’s last reported volume for Novavax is 9235960, 50.27% above its average volume of 6145970.
Novavax’s last close was $18.87, 92.42% below its 52-week high of $249.04.
The company’s growth estimates for the current quarter and the next is 215.8% and 247.6%, respectively.
Year-on-year quarterly revenue growth grew by 57.4%, now sitting on 1.4B for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Novavax’s stock is considered to be overbought (>=80).
Novavax’s Stock Yearly Top and Bottom Value
Novavax’s stock is valued at $19.99 at 18:41 EST, under its 52-week low of $20.46.
Novavax’s Moving Average
Novavax’s worth is way under its 50-day moving average of $41.71 and way under its 200-day moving average of $71.94.
More news about Novavax (NVAX).